Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Validity and Reliability of the Turkish Version of the Revised Bath CRPS Body Perception Disturbance Scale

NCT07858812 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-11-15
Last updated
2026-10-06

Condition(s) studied

Complex Regional Pain Syndrome (CRPS)

Study summary

This study aims to perform the cross-cultural adaptation of the Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale (r-B-CRPS-BPDS) into Turkish and to evaluate the validity and reliability of the Turkish version in adults with Complex Regional Pain Syndrome (CRPS). Adult participants diagnosed with CRPS according to the Budapest clinical diagnostic criteria will be included. Participants will complete the Turkish r-B-CRPS-BPDS together with measures of kinesiophobia, health-related quality of life, and pain intensity. CRPS clinical severity will also be assessed. Construct validity, internal consistency, test-retest reliability, measurement error, and floor and ceiling effects of the Turkish r-B-CRPS-BPDS will be evaluated. For test-retest reliability, clinically stable participants will complete the r-B-CRPS-BPDS again after 7-10 days. The study is intended to provide a culturally adapted, valid, and reliable Turkish version of the r-B-CRPS-BPDS for assessing body perception disturbance in individuals with CRPS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meet the criteria for a diagnosis of CRPS based on the Budapest clinical diagnostic criteria following clinical evaluation * Have complex regional pain syndrome affecting the upper or lower extremity * Be able to provide written informed consent to participate in the study * Have the cognitive ability to understand the forms and scales in Turkish Exclusion Criteria: * The presence of cognitive impairment or communication difficulties severe enough to prevent understanding of the scales or providing reliable responses * The presence of a central neurological disorder that could significantly affect body perception, somatosensory function, or limb function (e.g., stroke, multiple sclerosis, spinal cord injury) * The presence of a serious additional neurological or musculoskeletal disorder in the evaluated extremity, other than CRPS, that could significantly affect body perception and function * The presence of a severe psychiatric disorder severe enough to prevent reliable clinical evaluation and administration of the scales * Inability to complete the scales or demonstrate sufficient cooperation during the data collection process.

Primary outcome measure(s)

  • Construct Validity of the Turkish Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale — Day 1
    The construct validity of the Turkish version of the Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale (r-B-CRPS-BPDS) will be evaluated in adults with Complex Regional Pain Syndrome. The r-B-CRPS-BPDS assesses disturbances in body perception related to the affected limb, including feelings of ownership, awareness of limb position, emotional feelings toward the limb, perceived differences in size, temperature, pressure, and weight, desire for amputation, and mental representation of the affected limb. The total score ranges from 0 to 47, with higher scores indicating greater body perception disturbance. Construct validity will primarily be examined by assessing the association between the r-B-CRPS-BPDS total score and the Tampa Scale for Kinesiophobia total score. Associations with pain intensity, health-related quality of life, and clinical CRPS severity will also be examined.
  • Internal Consistency of the Turkish r-B-CRPS-BPDS — Day 1
    The internal consistency of the Turkish r-B-CRPS-BPDS will be evaluated using Cronbach's alpha coefficient and corrected item-total correlations. The analysis will determine the degree to which the items of the Turkish version consistently assess the construct of body perception disturbance in individuals with Complex Regional Pain Syndrome.
  • Test-Retest Reliability of the Turkish r-B-CRPS-BPDS — Baseline and 7-10 days after baseline
    Test-retest reliability will be evaluated in clinically stable participants by administering the Turkish r-B-CRPS-BPDS twice, with an interval of 7-10 days. Reliability will be assessed using the intraclass correlation coefficient (ICC), based on a two-way random-effects model, single measurement, and absolute agreement \[ICC(2,1)\]. Measurement error will additionally be evaluated using the standard error of measurement (SEM) and smallest detectable change (SDC).

Trial sites (1)

FacilityCityRegionStatus
Izmir Democracy University Cordaleo İzmir
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07858812 on ClinicalTrials.gov ↗ ← All trials in Turkey